20/20 Biolabs, Inc.(AIDX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,520 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
AIDX Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for 20/20 Biolabs, Inc. (AIDX), a Technology sector company. 13F Pro's AI-powered ranking engine scores AIDX at 29.7/100 on a 32-signal composite quality model, placing it at rank #2,520 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), 20/20 Biolabs, Inc. reports quarterly revenue of $730.6K, net income of $-1.5M. Top institutional holders of AIDX by reported 13-F value include Cresset Asset Management, HRT FINANCIAL, VANGUARD FIDUCIARY, based on the most recent SEC filings. AIDX trades on the Nasdaq exchange and files with the SEC under CIK 1139685. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AIDX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for 20/20 Biolabs, Inc. directly from SEC EDGAR. 20/20 Biolabs, Inc.'s 13F Pro composite quality score has ranged between 27 and 30 since 2026, currently 29.7 — a stable long-term trajectory across 8 quarterly and live scoring snapshots.
Revenue
Q2 2026
$730.6K
Net Income
Q2 2026
$-1.5M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+16.7% YoYNet Income
+32.7% YoYOperating Income
+41.3% YoYEPS (Diluted)
+34.5% YoYTotal Assets
+15.4% YoYOp. Cash Flow
+26.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $2.0M +16.7% | $1.8M | — |
| Net Income | $-3.7M +32.7% | $-5.6M | — |
| Operating Income | $-3.3M +41.3% | $-5.7M | — |
| EPS (Diluted) | $-0.38 +34.5% | $-0.58 | — |
| Total Assets | $4.1M +15.4% | $3.6M | — |
| Operating Cash Flow | $-1.9M +26.1% | $-2.6M | — |
Get alerted when AIDX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for 20/20 Biolabs, Inc. including:
Top Institutional Holders of AIDX
Cresset Asset Management, LLC
$132.0K240,122 shHRT FINANCIAL LP
$49.0K89,273 shVANGUARD FIDUCIARY TRUST CO
$28.6K52,087 shGEODE CAPITAL MANAGEMENT, LLC
$27.0K49,141 shUnion Bankshares Corp
$19.3K35,099 shVANGUARD CAPITAL MANAGEMENT LLC
$13.5K24,530 shCITADEL ADVISORS LLC
$12.8K23,205 shBANK OF AMERICA CORP /DE/
$7.2K13,024 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$5.5K10,014 shMCDONALD PARTNERS LLC
$1.5K2,800 sh
| Fund | Value | Shares |
|---|---|---|
| Cresset Asset Management, LLC | $132.0K | 240,122 |
| HRT FINANCIAL LP | $49.0K | 89,273 |
| VANGUARD FIDUCIARY TRUST CO | $28.6K | 52,087 |
| GEODE CAPITAL MANAGEMENT, LLC | $27.0K | 49,141 |
| Union Bankshares Corp | $19.3K | 35,099 |
| VANGUARD CAPITAL MANAGEMENT LLC | $13.5K | 24,530 |
| CITADEL ADVISORS LLC | $12.8K | 23,205 |
| BANK OF AMERICA CORP /DE/ | $7.2K | 13,024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $5.5K | 10,014 |
| MCDONALD PARTNERS LLC | $1.5K | 2,800 |
More Technology Companies
View all Technology →Put AIDX on your watchlist
Track score changes the day 20/20 Biolabs, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AIDX a good stock to buy?
13F Pro's AI-powered analysis of 20/20 Biolabs, Inc. (AIDX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AIDX are available on the AIDX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. AIDX is classified as a small company.
Which hedge funds own AIDX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AIDX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of 20/20 Biolabs, Inc.'s investment landscape.